India markets close in 1 hour 54 minutes

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.81-0.02 (-0.11%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close17.83
Open18.50
Bid0.00 x 1100
Ask0.00 x 1000
Day's range17.37 - 18.50
52-week range1.41 - 30.38
Volume972,864
Avg. volume702,415
Market cap928.033M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-1.43
Earnings date07-May-2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est32.20
  • Aclaris Announces Pricing of Public Offering of Common Stock
    GlobeNewswire

    Aclaris Announces Pricing of Public Offering of Common Stock

    WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the pub

  • Aclaris Announces Proposed Public Offering of Common Stock
    GlobeNewswire

    Aclaris Announces Proposed Public Offering of Common Stock

    WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwri

  • Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
    GlobeNewswire

    Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

    ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor ApproachATI-1777 was Generally Well ToleratedData Support Progression to Phase 2bManagement to Host Conference Call at 8:00 AM ET Today WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory disease